Investigating the Effects of Single Dose and Co-Supplementation of Vitamin D and Omega-3 in women with poly cystic ovary syndrome

Not Applicable

Conditions: polycystic ovary syndrome.
polycystic ovary syndrome
E28.2

Registration Number: IRCT20100223003408N7

Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 107

Inclusion Criteria

This syndrome is defined by the Rotterdam Diagnostic Criteria by Gynecologist
Excluding any drug or surgical treatment to treat clinical symptoms associated with polycystic ovary syndrome except ocp
No history of any allergy, intolerance or harmful drug reaction to the studied supplements
Age range ..18-45
Being within the BMI range of 18.5-40
Ability to understand study objectives and provide written informed consent
Residence in Shiraz and willingness to participate in the study

Exclusion Criteria

Suffering from hormonal disorders including Edison's disease, Cushing's disease, hyperparathyroidism, hypo- or hyperthyroidism
Having history of chronic diseases including cancer, heart disease, diabetes, stroke, fibromyalgia, kidney, or liver defects
Having history of food and drug allergies
Starting drug or surgical therapy for clinical symptoms associated with PCOS except oral contraceptive pills (OCPs)
Smoking or any drug addiction
Pregnancy and lactation
Being on a special diet in the last year
Using any dietary supplement,
Having oral or injectable nutritional supplements containing vitamin D in the last 3 months
Consuming nutritional supplements containing fish oil or Omega-3 fatty acids in the last 3 months
Having fish in the diet more than 3 servings per week during last 3 months
History of severe side effects or symptoms of poisoning with the current study supplements
Lack of adherence to the study protocol

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TG. Timepoint: Beginning and end of the study (first week and eighth week). Method of measurement: Autoanalyzer.;TC:total cholesterol. Timepoint: Beginning and end of the study (first week and eighth week). Method of measurement: Autoanalyzer.;HDL-C:high-density lipoprotein cholesterol. Timepoint: Beginning and end of the study (first week and eighth week). Method of measurement: Autoanalyzer.;LDL-C:Low-density lipoprotein cholesterol. Timepoint: Beginning and end of the study (first week and eighth week). Method of measurement: Autoanalyzer.

Secondary Outcome Measures